13.23
Systemy dostarczania leków o zmodyfikowanym uwalnianiu: systemy o programowanej szybkości uwalniania II
Systemy dostarczania leków o programowanej szybkości uwalniania uwalniają substancje lecznicze w sposób kontrolowany w celu utrzymania stężeń terapeut…
Systemy dostarczania leków z programem tempowym mogą mieć trzy projekty: rezerwuar, matrycę lub hybrydę.
Systemy rezerwuarowe otaczają rdzeń leku w warstwie lub membranie kontrolującej szybkość.
Typy nieobrzęczniające wykorzystują polimery etylowocelulozy i polimetaakrylanu do kontroli uwalniania leków poprzez grubość, nierozpuszczalność, powolne rozpuszczanie lub porowatość. Typy kontrolowane przez obrzęk często wykorzystują polimery, takie jak HPMC, aby opóźnić uwalnianie leku aż do nawilżenia błony.
Systemy matrycowe osadzają lek w materiale opóźniającym uwalnianie.
Macierze hydrofilowe wykorzystują polimery pęczniące, takie jak HPMC, natomiast macierze hydrofobowe używają wosków lub etylocelulozy. Macierze hydrofobowe mogą być porowate, z lekiem zmieszanym z polimerem, lub nieporowate, gdzie lek rozprasza się w stopionym polimerze.
Systemy hybrydowe osadzają lek w matrycy pokrytej materiałem opóźniającym uwalnianie uwalniania, który dodatkowo pokrywa się polimerem kontrolującym uwalnianie. Ta konstrukcja łączy stałe uwalnianie systemów rezerwuarowych z trwałością urządzeń matrycowych, skutecznie kontrolując uwalnianie leków.
View the full transcript and gain access to JoVE Core videos
Q1: What are the three main designs of rate-programmed drug delivery systems?
Rate-programmed drug delivery systems follow three designs: reservoir, matrix, and hybrid. Reservoir systems enclose the drug core within a rate-controlling membrane. Matrix systems embed the drug in a release-retarding material. Hybrid systems combine both approaches by embedding drug in a matrix and coating it with a polymer membrane, merging the consistent release of reservoir systems with the structural durability of matrix systems.
Q2: How do non-swelling reservoir systems control drug release?
Non-swelling reservoir systems use polymers like ethyl cellulose and polymethacrylates that do not hydrate in aqueous media. These polymers control drug release through membrane thickness, insolubility, slow dissolution, or porosity. This design is used in coated particles, pellets, or tablets to achieve predictable, sustained drug delivery without requiring membrane hydration.
Q3: What is the difference between hydrophilic and hydrophobic matrix systems?
Hydrophilic matrices use water-swellable polymers like HPMC that form porous structures and allow drug diffusion through the swollen matrix. Hydrophobic matrices use slowly soluble or insoluble materials like waxes or ethyl cellulose. Hydrophobic matrices can be porous, with drug mixed into polymer particles, or nonporous, with drug dispersed in molten polymer for controlled release.
Q4: How do swelling-controlled reservoir systems delay drug release?
Swelling-controlled reservoir systems use polymers such as HPMC that hydrate in aqueous media. Drug release begins only after the membrane absorbs water and hydrates, resulting in a delayed onset followed by steady release. This design allows precise timing of drug delivery initiation, making it useful for drugs requiring delayed therapeutic action.
Q5: What advantage do hybrid drug delivery systems offer over single-design systems?
Hybrid systems embed drug in a matrix and coat it with a polymer membrane, combining the consistent drug release of reservoir systems with the structural durability of matrix systems. This design provides superior control over drug delivery by leveraging the steady-state kinetics of reservoirs while maintaining the mechanical stability and longevity of matrix devices.
Q6: How does membrane thickness affect drug release in reservoir systems?
In non-swelling reservoir systems, membrane thickness is a critical parameter controlling drug release rate. Thicker membranes slow drug diffusion through the polymer, extending release duration, while thinner membranes accelerate release. By adjusting ethyl cellulose or polymethacrylate membrane thickness, manufacturers can precisely program drug release kinetics to match therapeutic requirements.
Q7: What role does porosity play in controlling drug release from matrix systems?
Porosity in matrix systems, particularly in hydrophobic matrices, creates pathways for drug diffusion and dissolution. Porous hydrophobic matrices mix drug and polymer particles, allowing fluid penetration and drug release through interconnected pores. Nonporous systems rely on drug solubility and polymer erosion, offering different release profiles suited to specific drug properties and therapeutic goals.